The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | TOURMALINE-AL1: ixazomib for AL amyloidosis
Angela Dispenzieri
• 31 May 2020
Angela Dispenzieri, MD, of the Mayo Clinic College of Medicine, Rochester, MN, touches on the results of the TOURMALINE-AL1 study (NCT01659658), a randomized study evaluating ixazomib and dexamethasone in the relapsed/refractory amyloid light-chain (AL) amyloidosis setting. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).
